Foghorn Therapeutics Newsroom

H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Cuts Target Price to $13

Moomoo NewsDec 17 06:31 ET

Morgan Stanley Maintains Foghorn Therapeutics(FHTX.US) With Hold Rating, Maintains Target Price $9

Moomoo NewsDec 16 20:31 ET

Foghorn Therapeutics: Hold Rating Amid Strategic Pivot and Uncertainty in Drug Development

TipRanksDec 16 19:57 ET

Jefferies Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $14

BenzingaDec 16 14:10 ET

Foghorn Therapeutics Analyst Ratings

BenzingaDec 16 14:09 ET

Wedbush Cuts Price Target on Foghorn Therapeutics to $10 From $13, Keeps Outperform Rating

MT NewswiresDec 16 11:06 ET

Jefferies Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Cuts Target Price to $14

Moomoo NewsDec 16 09:31 ET

Analysts Conflicted on These Healthcare Names: Solid Biosciences (SLDB), Foghorn Therapeutics (FHTX) and KalVista Pharmaceuticals (KALV)

TipRanksDec 5 13:33 ET

TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating

Moomoo NewsNov 5 08:35 ET

H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsNov 5 06:36 ET

TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating

Moomoo NewsNov 4 19:33 ET

TD Cowen Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)

TipRanksNov 4 19:19 ET

Foghorn Therapeutics Analyst Ratings

BenzingaSep 24 07:30 ET

Morgan Stanley Adjusts Foghorn Therapeutics Price Target to $9 From $6, Maintains Equalweight Rating

MT NewswiresSep 23 09:45 ET

Jefferies Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $18

Moomoo NewsSep 3 05:32 ET

Foghorn Therapeutics Analyst Ratings

BenzingaAug 19 09:57 ET

Evercore Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsAug 19 08:31 ET

Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)

TipRanksAug 19 06:42 ET

Evercore Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $20

Moomoo NewsAug 19 06:31 ET

Foghorn Therapeutics Drug Candidates FHD-286 and FHD-909 Show Promise in Early Trials, Justifying Buy Rating

TipRanksAug 12 06:44 ET